Newsletter
Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

JAMA Editor’s Summary

Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the issue.
December 21, 2021

Maintenance Infliximab for Immune-Mediated Inflammatory Diseases, Omega-3 Fatty Acids for Depression, DOACs and Atrial Fibrillation, and more

Editor’s Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the December 21, 2021 issue.

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
Episode #123 – Is It Getting Worse to Be a Nurse? John and David tackle the shortage, while exploring the implications it can have for our healthcare system as a whole.